BG104507A - Комбинирана терапия за лечение на спин - Google Patents

Комбинирана терапия за лечение на спин Download PDF

Info

Publication number
BG104507A
BG104507A BG104507A BG10450700A BG104507A BG 104507 A BG104507 A BG 104507A BG 104507 A BG104507 A BG 104507A BG 10450700 A BG10450700 A BG 10450700A BG 104507 A BG104507 A BG 104507A
Authority
BG
Bulgaria
Prior art keywords
compound
indinavir
pharmaceutically acceptable
acceptable salt
ester
Prior art date
Application number
BG104507A
Other languages
Bulgarian (bg)
English (en)
Inventor
Joseph P. Vacca
Jiunn H. Lin
Kuang C. Yen
Jeffrey A. Chodakewitz
Paul J. Deutsch
William D. Ju
Original Assignee
Merck & Co.,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807938.7A external-priority patent/GB9807938D0/en
Priority claimed from GBGB9819590.2A external-priority patent/GB9819590D0/en
Application filed by Merck & Co.,Inc. filed Critical Merck & Co.,Inc.
Publication of BG104507A publication Critical patent/BG104507A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG104507A 1997-11-13 2000-06-05 Комбинирана терапия за лечение на спин BG104507A (bg)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6542197P 1997-11-13 1997-11-13
GBGB9807938.7A GB9807938D0 (en) 1998-04-15 1998-04-15 Combination therapy for the treatment of AIDS
US9094098P 1998-06-26 1998-06-26
GBGB9819590.2A GB9819590D0 (en) 1998-09-08 1998-09-08 Combination therapy for the treatment of aids
PCT/US1998/024097 WO1999025352A1 (en) 1997-11-13 1998-11-12 Combination therapy for the treatment of aids

Publications (1)

Publication Number Publication Date
BG104507A true BG104507A (bg) 2001-03-30

Family

ID=27451773

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104507A BG104507A (bg) 1997-11-13 2000-06-05 Комбинирана терапия за лечение на спин

Country Status (24)

Country Link
EP (1) EP1044000B1 (xx)
JP (1) JP2001522889A (xx)
KR (1) KR20010032055A (xx)
CN (1) CN1285747A (xx)
AR (1) AR013758A1 (xx)
AT (1) ATE218866T1 (xx)
AU (1) AU749795B2 (xx)
BG (1) BG104507A (xx)
BR (1) BR9814146A (xx)
CA (1) CA2309164A1 (xx)
CO (1) CO4970782A1 (xx)
DE (1) DE69806062T2 (xx)
EA (1) EA200000513A1 (xx)
ES (1) ES2177103T3 (xx)
HU (1) HUP0100365A3 (xx)
ID (1) ID24922A (xx)
IL (1) IL135994A0 (xx)
IS (1) IS5481A (xx)
NO (1) NO20002481L (xx)
PE (1) PE20000020A1 (xx)
PL (1) PL340430A1 (xx)
SK (1) SK6842000A3 (xx)
TR (1) TR200001938T2 (xx)
WO (1) WO1999025352A1 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US7462733B2 (en) 2001-07-30 2008-12-09 University Of Southern California Preparation and use of α-keto phosphonates
CN105596356A (zh) 2003-01-14 2016-05-25 吉里德科学公司 用于联合抗病毒治疗的组合物和方法
GB2400553A (en) * 2003-04-14 2004-10-20 Cipla Ltd Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL314984A1 (en) * 1993-12-15 1996-09-30 Merck & Co Inc Hiv protease inhibitors

Also Published As

Publication number Publication date
ES2177103T3 (es) 2002-12-01
ATE218866T1 (de) 2002-06-15
CN1285747A (zh) 2001-02-28
EP1044000A1 (en) 2000-10-18
BR9814146A (pt) 2000-10-03
CA2309164A1 (en) 1999-05-27
DE69806062T2 (de) 2003-03-20
AR013758A1 (es) 2001-01-10
EP1044000B1 (en) 2002-06-12
TR200001938T2 (tr) 2001-07-23
HUP0100365A2 (hu) 2002-05-29
IS5481A (is) 2000-05-09
SK6842000A3 (en) 2000-12-11
IL135994A0 (en) 2001-05-20
AU749795B2 (en) 2002-07-04
PE20000020A1 (es) 2000-01-27
HUP0100365A3 (en) 2002-06-28
DE69806062D1 (de) 2002-07-18
WO1999025352A1 (en) 1999-05-27
EA200000513A1 (ru) 2000-10-30
JP2001522889A (ja) 2001-11-20
NO20002481L (no) 2000-07-12
NO20002481D0 (no) 2000-05-12
KR20010032055A (ko) 2001-04-16
PL340430A1 (en) 2001-02-12
CO4970782A1 (es) 2000-11-07
ID24922A (id) 2000-08-31
AU1522599A (en) 1999-06-07

Similar Documents

Publication Publication Date Title
DE69534549T2 (de) Kombination von retroviralen Proteasehemmern
KR101524165B1 (ko) Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
AU2006325404B2 (en) Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
US6180634B1 (en) Combination therapy for the treatment of AIDS
EP1044000B1 (en) Combination therapy for the treatment of aids
EP0806957B1 (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir adn the reverse transcriptase inhibitor 3tc together with azt.
CA2703918C (en) Solid pharmaceutical dosage forms of atazanavir and ritonavir combinations
KR900006993B1 (ko) 아테롬성 동맥경화증 치료제로서의 dl-5-[(2-벤질-3,4-디하이드로-2H-벤조피란-6-일)메틸]티아졸리딘-2,4-디온
AU2863895A (en) Combination therapy for hiv infection
CA2197207C (en) Hiv protease inhibitor combination
CN108440446B (zh) 含有肟基片段的苯并噻嗪-4-酮类化合物及其制备方法
CZ20001752A3 (cs) Farmaceutické prostředky obsahující kombinaci pro léčbu AIDS
WO2022024649A1 (ja) 感冒剤及び抗ウイルス剤
JPH05301816A (ja) 抗エイズ剤
NZ732033B2 (en) Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
MXPA99011018A (en) Sulfate salt of an hiv protease inhibitor having an improved oral absorption and bioavailability